Daniel S. Harrison

Daniel S. Harrison

Auto-generated profile, based on publicly available information

Daniel S. Harrison

Department of Neurology, Boston University School of Medicine, MA; and

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2017 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
RNRobert Y. North
Robert Y. North
LRLaurence Rhines
Laurence Rhines
CTClaudio E. Tatsui
Claudio E. Tatsui
GRGanesh Rao
Ganesh Rao
PDPatrick M. Dougherty
Patrick M. Dougherty
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect experienced by cancer patients receiving treatment with paclitaxel. The voltage-gated sodium channel 1.7 (Nav1.7) plays an important role in multiple preclinical models of neuropathic pain and in inherited human pain phenotypes, and its gene expression is increased in dorsal root ganglia (DRGs) of paclitaxel-treated rats. Hence, the potential of change in the expression and function of Nav1.7 protein in DRGs from male rats with paclitaxel-related CIPN and from male and female humans with cancer-related neuropathic pain was tested here. Double immunofluorescence in CIPN rats showed that Nav1.7 was upregulated in small DRG neuron somata, especially those also expressing calcitonin gene-related peptide (CGRP), and in central processes of these cells in the superficial spinal dorsal horn. Whole-cell patch-clamp recordings in rat DRG neurons revealed that paclitaxel induced an enhancement of ProTx II (a selective Nav1.7 channel blocker)-sensitive sodium currents. Bath-applied ProTx II suppressed spontaneous action potentials in DRG neurons occurring in rats with CIPN, while intrathecal injection of ProTx II significantly attenuated behavioral signs of CIPN. Complementarily, DRG neurons isolated from segments where patients had a history of neuropathic pain also showed electrophysiological and immunofluorescence results indicating an increased expression of Nav1.7 associated with spontaneous activity. Nav1.7 was also colocalized in human cells expressing transient receptor potential vanilloid 1 and CGRP. Furthermore, ProTx II decreased firing frequency in human DRGs with spontaneous action potentials. This study suggests that Nav1.7 may provide a potential new target for the treatment of neuropathic pain, including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEMENTThis work demonstrates that the expression and function of the voltage-gated sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN), the most common treatment-limiting side effect of all the most common anticancer therapies. This is key as gain-of-function mutations in human Nav1.7 recapitulate both the distribution and pain percept as shown by CIPN patients. This work also shows that Nav1.7 is increased in human DRG neurons only in dermatomes where patients are experiencing acquired neuropathic pain symptoms. This work therefore has major translational impact, indicating an important novel therapeutic avenue for neuropathic pain as a class.

30 September 2015 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
PAPavel Adamek
Pavel Adamek
HZHaijun Zhang
Haijun Zhang
CTClaudio Esteves Tatsui
Claudio Esteves Tatsui
LRLaurence Rhines
Laurence Rhines
PDPatrick M. Dougherty
Patrick M. Dougherty
Peripheral neuropathy is dose limiting in paclitaxel cancer chemotherapy and can result in both acute pain during treatment and chronic persistent pain in cancer survivors. The hypothesis tested was that paclitaxel produces these adverse effects at least in part by sensitizing transient receptor potential vanilloid subtype 1 (TRPV1) through Toll-like receptor 4 (TLR4) signaling. The data show that paclitaxel-induced behavioral hypersensitivity is prevented and reversed by spinal administration of a TRPV1 antagonist. The number of TRPV1+neurons is increased in the dorsal root ganglia (DRG) in paclitaxel-treated rats and is colocalized with TLR4 in rat and human DRG neurons. Cotreatment of rats with lipopolysaccharide from the photosynthetic bacteriumRhodobacter sphaeroides(LPS-RS), a TLR4 inhibitor, prevents the increase in numbers of TRPV1+neurons by paclitaxel treatment. Perfusion of paclitaxel or the archetypal TLR4 agonist LPS activated both rat DRG and spinal neurons directly and produced acute sensitization of TRPV1 in both groups of cells via a TLR4-mediated mechanism. Paclitaxel and LPS sensitize TRPV1 in HEK293 cells stably expressing human TLR4 and transiently expressing human TRPV1. These physiological effects also are prevented by LPS-RS. Finally, paclitaxel activates and sensitizes TRPV1 responses directly in dissociated human DRG neurons. In summary, TLR4 was activated by paclitaxel and led to sensitization of TRPV1. This mechanism could contribute to paclitaxel-induced acute pain and chronic painful neuropathy.SIGNIFICANCE STATEMENTIn this original work, it is shown for the first time that paclitaxel activates peripheral sensory and spinal neurons directly and sensitizes these cells to transient receptor potential vanilloid subtype 1 (TRPV1)-mediated capsaicin responses via Toll-like receptor 4 (TLR4) in multiple species. A direct functional interaction between TLR4 and TRPV1 is shown in rat and human dorsal root ganglion neurons, TLR4/TRPV1-coexpressing HEK293 cells, and in both rat and mouse spinal cord slices. Moreover, this is the first study to show that this interaction plays an important role in the generation of behavioral hypersensitivity in paclitaxel-related neuropathy. The key translational implications are that TLR4 and TRPV1 antagonists may be useful in the prevention and treatment of chemotherapy-induced peripheral neuropathy in humans.

2 April 2018 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Open access
DHDaniel Harrison
Daniel Harrison
PMPaul Mehta
Paul Mehta
MEMichael A. van Es
Michael A. van Es
ESElijah Stommel
Elijah Stommel
VDVivian E. Drory
Vivian E. Drory
TCthe Pooled Resource Open-Access ALS Clinical Trials Consortium
the Pooled Resource Open-Access ALS Clinical Trials Consortium
Objective: To identify differences in demographics, disease characteristics, treatments, and co-morbidities between patients with “amyotrophic lateral sclerosis (ALS) reversals” and those with typically progressive ALS. Methods: Cases of possible ALS reversals were found in prior publications, in the Duke ALS clinic, through self-referral or referral from other Neurologists, and on the internet. Of 89 possible reversals identified, 36 cases were included because chart or literature review confirmed their diagnosis and a robust, sustained improvement in at least one objective measure. Controls were participants in the Pooled Resource Open-Access ALS Clinical Trials database and the National ALS Registry. Cases and controls were compared using descriptive statistics. Results: ALS reversals were more likely to be male, have limb onset disease, and initially progress faster. The prevalences of myasthenia gravis (MG) and purely lower motor neuron disease in cases were higher than estimates of these prevalences in the general population. The odds of taking curcumin, luteolin, cannabidiol, azathioprine, copper, glutathione, vitamin D, and fish oil were greater for cases than controls. Conclusions: When compared to patients with typically progressive ALS, patients with reversals differed in their demographics, disease characteristics, and treatments. While some of these patients may have had a rare antibody-mediated ALS mimicker, such as atypical myasthenia gravis, details of their exams, EMGs and family histories argue that this was unlikely. Instead, our data suggest that ALS reversals warrant evaluation for mechanisms of disease resistance and that treatments associated with multiple ALS reversals deserve further study.

15 March 2024 in Critical Care Medicine
Verified
Journal Article
Closed access
DHDaniel S. Harrison
Daniel S. Harrison
ESErika J. Sigman
Erika J. Sigman
JCJudy H. Ch’aNg
Judy H. Ch’aNg
ASAarti Md Sarwal
Aarti Md Sarwal
ACAbigale Dnp Celotto
Abigale Dnp Celotto
CACatherine S.W. Albin
Catherine S.W. Albin
OBJECTIVES: To define consensus entrustable professional activities (EPAs) for neurocritical care (NCC) advanced practice providers (APPs), establish validity evidence for the EPAs, and evaluate factors that inform entrustment expectations of NCC APP supervisors. DESIGN: A three-round modified Delphi consensus process followed by application of the EQual rubric and assessment of generalizability by clinicians not affiliated with academic medical centers. SETTING: Electronic surveys. SUBJECTS: NCC APPs (n = 18) and physicians (n = 12) in the United States with experience in education scholarship or APP program leadership. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The steering committee generated an initial list of 61 possible EPAs. The panel proposed 30 additional EPAs. A total of 47 unique nested EPAs were retained by consensus opinion. The steering committee defined six core EPAs addressing medical knowledge, procedural competencies, and communication proficiency which encompassed the nested EPAs. All core EPAs were retained and subsequently met the previously described cut score for quality and structure using the EQual rubric. Most clinicians who were not affiliated with academic medical centers rated each of the six core EPAs as very important or mandatory. Entrustment expectations did not vary by prespecified groups. CONCLUSIONS: Expert consensus was used to create EPAs for NCC APPs that reached a predefined quality standard and were important to most clinicians in different practice settings. We did not identify variables that significantly predicted entrustment expectations. These EPAs may aid in curricular design for an EPA-based assessment of new NCC APPs and may inform the development of EPAs for APPs in other critical care subspecialties.

1 March 2023 in Neurology Education
Verified
Journal Article
Open access
PDF file
DHDaniel S. Harrison
Daniel S. Harrison
MNMargaret Naclerio
Margaret Naclerio
KSKathryn Swider
Kathryn Swider
CGCarl Garrubba
Carl Garrubba
AYAndrew T. Yu
Andrew T. Yu
CDChristopher Doughty
Christopher Doughty
Background and Objectives A growing number of advanced practice providers (APPs) are entering neurologic practice, and educational initiatives focused on postgraduate training in neurology for these providers are growing in turn. Neurologic education in APP degree programs is not well defined, which limits the ability to tailor these initiatives to the specific needs of APPs. We aim to describe neurologic education in physician assistant (PA) degree programs to better inform these efforts. Methods The 2018 American Academy of Neurology clerkship director survey was adapted for directors of PA programs via an iterative approach. The survey was distributed to program directors (PDs) of accredited programs in Fall 2021 and again in Spring 2022 for nonresponders. Simultaneously, websites of accredited programs were systematically reviewed for content related to neurologic education. Results Sixty of 255 contacted PDs completed the survey (23.5%). All PDs reported education in selected neuroscience topics. Neuroradiology instruction was included less frequently (66.7%) than neuroanatomy (91.7%) or neurologic examination techniques (95.0%). Twenty-six PDs (43.3%) reported a dedicated neuroscience course; 53 of 260 websites reviewed identified dedicated neuroscience courses (20.8%, k = 0.41). Directors of 10 (38.5%) reported neuroscience courses were neuroscience trained. Only 1 program required a neurology clinical rotation in both the website review (0.4%) and the PD survey (1.7%, k = 1.00). Elective neurology rotations were offered by 51 programs (85.0%) and used by less than 20% of students in 46 programs (92.0%). More programs with dedicated neuroscience didactics (80.0% vs 74.2%) and offerings in clinical neurology (78.7% vs 66.7%) reported graduates pursuing careers in neurology, but these differences were not statistically significant. Discussion Survey respondents reported the inclusion of most of the queried preclinical neuroscience topics, typically distributed throughout the curriculum. Dedicated neuroscience courses were less common and most commonly not taught by a neurologist or neurology APP. Clinical neurology rotations are almost never required, but most programs offer an elective. These results suggest opportunities for augmenting neurologic education in APP degree programs, including encouraging students to take clinical neurology rotations and increasing exposure to APPs practicing neurology. These findings additionally inform key targets for postgraduate educational initiatives.

1 March 2025 in Neurology Education
Verified
Journal Article
Open access
KSKathryn Swider
Kathryn Swider
CCCalli Cook
Calli Cook
JDJustin DiLibero
Justin DiLibero
KHKathryn E. Hall
Kathryn E. Hall
MNMargaret Naclerio
Margaret Naclerio
DHDaniel Harrison
Daniel Harrison
A growing number of nurse practitioners (NPs) are entering neurologic practice. Postgraduate educational needs of NPs are partly dictated by previous neurologic educational experience, which is not well defined. We aim to describe neurologic education in NP programs to better inform efforts to develop tailored educational initiatives. A website review was performed to identify accredited NP programs and program leaders. A previously developed survey designed to facilitate a description of neurologic education in physician assistant (PA) programs was adapted for NP program leaders by an iterative approach. The survey was distributed in spring and fall 2023. Three hundred and thirty-three Family NP, 140 Adult-Gerontologic Primary Care NP, and 136 Adult-Gerontologic Acute Care NP registered programs were identified. Leaders of 206 programs completed the survey (response rate = 34.9%). Two hundred four respondents (99.0%) reported neuroscience didactics included within their curriculum, typically contained within core, discipline-based courses. Neurologic disease and examination (n = 201, 98%) were covered most while lesion localization (n = 37, 18.0%) and neuroradiology (n = 50, 24.3%) were taught least often. Of 201 respondents who indicated that neurologic examination is included, 175 (87.1%) reported a hands-on approach. Didactic neuroscience instructors were specialized in clinical neurology in 109 programs (53.4%). One hundred sixty-nine programs (82.0%) offer a neurology clinical rotation, typically as an elective. Of respondents who provided an estimate, most reported that 10% or fewer of their students complete a neurology clinical rotation per year (n = 62, 77.5%). The most frequently reported barrier to offering clinical placement in neurology was lack of neurology preceptors (n = 85, 56.6%). Programs reporting graduates pursuing careers in neurology were associated with larger size, acute care track, and neurology NP as a didactic neuroscience instructor. Lesion localization and neuroradiology are important targets for postgraduate training of NPs entering neurologic practice. Recruiting neurology NPs to teach neuroscience didactics may increase programs with students pursuing careers in neurology. Availability of clinical neurology rotations is not universal in NP programs. Encouraging neurology clinicians, including PAs and physicians, to precept NP students could help increase access to clinical neurology rotations. These results highlight important opportunities for augmenting neurologic education during and after NP programs.